Oncology Clinical Trials in New York, NY
As of September 2026, 805 paid clinical trials are recruiting for Oncology in New York, New York. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in New York
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Study of Romosozumab in People With Breast Cancer and Osteoporosis
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
A Study of Lung Cancer Risk
811 clinical trials for Oncology
·Clear filters·Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Top Research Study Locations in New York
Researchers run research studies in New York, NY at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Memorial Sloan Kettering Cancer Center | Breast Cancer, Prostate Cancer, Endometrial Cancer | 460 |
| NYU Langone Health | Prostate Cancer, Lung Cancer, Major Depressive Disorder | 318 |
| Icahn School of Medicine at Mount Sinai | Crohn's Disease, Myelofibrosis, Prostate Cancer | 252 |
| Columbia University Irving Medical Center | Obesity, Insulin Resistance, Alzheimer Disease | 175 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | Breast Cancer, Multiple Myeloma, Lung Cancer | 155 |
| Weill Cornell Medicine | Depression, Heart Failure, Prostate Cancer | 139 |
| Mount Sinai Hospital | Heart Failure, Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8 | 121 |
| Columbia University Medical Center | Breast Cancer, Advanced Solid Tumor, Coronary Artery Disease | 119 |
| Columbia University | Amyotrophic Lateral Sclerosis, Obstetrical Complications, Colorectal Cancer | 111 |
| Hospital for Special Surgery | Systemic Lupus Erythematosus, Opioid Use, Rheumatoid Arthritis | 64 |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Solid Neoplasm, Anatomic Stage II Breast Cancer AJCC v8 | 51 |
| Lenox Hill Hospital | Anatomic Stage II Breast Cancer AJCC v8, Atrial Fibrillation, Head and Neck Squamous Cell Carcinoma | 45 |
| Mount Sinai West | Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer, Intracerebral Hemorrhage | 45 |
| Mount Sinai | Ovarian Cancer, AML, Advanced Solid Tumors | 44 |
| NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | Malignant Solid Neoplasm, Acute Myeloid Leukemia, Neuroblastoma | 44 |
| Weill Cornell Medical College | ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome | 43 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activites) | Breast Cancer, Prostate Cancer, Pancreatic Cancer | 40 |
| NYP/Weill Cornell Medical Center | B Acute Lymphoblastic Leukemia, Malignant Solid Neoplasm, Anatomic Stage IV Breast Cancer AJCC v8 | 35 |
| New York University | Inflammatory Bowel Disease (IBD), Acute or Chronic Coronary Artery Disease, Adenine Phosphoribosyltransferase Deficiency | 29 |
| Memorial Sloan-Kettering Cancer Center | Advanced Solid Tumor, Breast Cancer, Colorectal Cancer (CRC) | 23 |
| Mount Sinai Chelsea | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | 22 |
| Manhattan Eye Ear and Throat Hospital | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8 | 21 |
| NYU Langone | Acute Gastrointestinal Bleeding, Advanced Breast Cancer, Advanced Cancer | 21 |
| Montefiore Medical Center | Mitral Regurgitation, Coronary Artery Disease, AML, Adult | 20 |
| The Mount Sinai Hospital | Homocystinuria, Intracerebral Hemorrhage, Ischemic Stroke | 18 |
Active & Upcoming Studies in New York (2026)
Recruiting trials in New York grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (1,129 active studies)
- Improving Affordability in Cancer Care Through Economic Screening and Support (I-ACCESS) · UNC Lineberger Comprehensive Cancer Center
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma · Phase 3 · AbbVie
Neurology & pain (198 active studies)
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau · Phase 1 · Columbia University
- Optimal Dosing of High-Intensity Locomotor Training for Step Attainment and Locomotor Outcomes in Stroke Patients Undergoing Acute Inpatient Rehabilitation · NYU Langone Health
Cardiovascular (195 active studies)
- Know Your Pressures NYC · Columbia University
- Optimizing Care For Management Of Hard To Control Hypertension In Low-Income Patients Across Family Health Centers In New York City · NYU Langone Health
Mental health & behavior (111 active studies)
- Whole-Body Hyperthermia for Mood and Anxiety Disorders · Weill Medical College of Cornell University
- Permanent Supportive Housing Overdose Prevention+ Study · NYU Langone Health
Diabetes & metabolic (106 active studies)
- South Asians With Type 2 Diabetes at Risk for Depression · NYU Langone Health
- Adaptive Dietary Intervention (ADI) for Asian Americans With Type 2 Diabetes · NYU Langone Health
HIV / STI (44 active studies)
- A Social Network Approach to Improve HIV Prevention and Substance Use Treatment For People Who Use Drugs · NYU Langone Health
- Expanding HOPE Liver · National Institute of Allergy and Infectious Diseases (NIAID)
Pediatric (34 active studies)
- Bilevel Positive Airway Pressure (BPAP) for Severe Asthma · Columbia University
- Neonatal Neurological Observation With Video AI · Artemis AI Labs
Vaccines (19 active studies)
- A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
- SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction · Phase 2 · Icahn School of Medicine at Mount Sinai
Eye & vision (15 active studies)
- Know Your Pressures NYC · Columbia University
- TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED) · Phase 4 · NYU Langone Health
Common conditions studied in New York
- Breast Cancer (92 active studies)
- Prostate Cancer (74 active studies)
- Multiple Myeloma (44 active studies)
- Colorectal Cancer (42 active studies)
- Ovarian Cancer (41 active studies)
- Endometrial Cancer (37 active studies)
Leading research sponsors in New York
- Memorial Sloan Kettering Cancer Center
- NYU Langone Health
- Columbia University
- Icahn School of Medicine at Mount Sinai
- Weill Medical College of Cornell University
Frequently asked questions
How many paid clinical trials are currently recruiting in New York?
There are approximately 3,375 recruiting clinical trials in New York, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New York pay participants?
Most recruiting trials in New York compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New York?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New York?
The most common conditions under active study in New York include Breast Cancer (92), Prostate Cancer (74), Multiple Myeloma (44), Colorectal Cancer (42), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New York?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New York on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New York?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New York?
Recruiting research sites in New York include Memorial Sloan Kettering Cancer Center, NYU Langone Health, Icahn School of Medicine at Mount Sinai, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New York right now?
The largest active categories in New York are Cancer & tumors (1,129), Neurology & pain (198), Cardiovascular (195). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.